All studies
Endocrinology · EHR · China

Zhao 2026

Type 2 diabetes

QBA performedITTSuperiorityAcademia, Industry2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Three-point MACE
vs LEADER·HR·Efficacy
0.870.78–0.97
0.900.81–1.01
not pooledMajor deviation

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
1:1 propensity-score matching
Analysis method
Matched Cox proportional hazards model
Missing data
Complete case
DAG
No
QBA
Yes

Data and sample

Data type
EHR
Data sources
1
Geography
China
Eligible sample
17772
Treated
8886
Control
8886
Emulations
1
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
COI institutions
Relationships listed in the report
Funding
Declared: Public, Private
Funders
Funding listed in the report

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Zhao_LEADER
DOI
10.3389/fendo.2026.1777954
Affiliations
Chinese academic institutions and LinkDoc data platform
Sector
Academia, Industry
Target trials (study level)
LEADER
Registration
NCT01179048